부산대학교 도서관

Background: Autoimmune conditions in B‐cell lymphomas are frequent. Steroids are standard of care, but many patients require other immunosuppressive agents. Ibrutinib is a Bruton Tyrosine Kinase inhibitor that is approved for B‐cell indolent lymphoma treatment. We evaluated the use of ibrutinib in previously treated hematologic immune manifestations associated with B‐cell lymphomas. Results: We conducted a retrospective multicentric observational study. Patients presenting with active, relapsed/refractory B‐cell lymphoma associated hematological immune manifestation (autoimmune cytopenia, acquired immune‐mediated bleeding disorders) were included. Twenty‐five patients were identified. Median age at ibrutinib introduction was 69 years (range 44–84) and median number of previous treatment lines before ibrutinib was 2 (1–7). Twenty‐two patients (88%) were on concomitant stable treatment at inclusion. Within a median exposure of 8 months (2–35), overall response rate to ibrutinib on immune manifestations was 76% (95% CI, 54.9–90.6); complete response rate 44%. Fourteen patients (63%) were able to be weaned from concomitant treatments. Fourteen patients (56%) presented treatment‐related adverse events, mostly Grade 1 or 2. Conclusions: Ibrutinib in this setting provides good efficacy and safety profile. Clinical trials are needed to define subgroups of patients who will benefit from this strategy and establish its place in the therapeutic arsenal. [ABSTRACT FROM AUTHOR]